Background The clinical management of intracranial aneurysms is debated in many countries because of the associated disability risk and costs. Therefore, estimating the costs and explaining their variability will provide important information for decision makers. Objective We aimed to evaluate the acute and post-acute health costs of intracranial aneurysm management and to explain the variability in these costs in the Italian National Health System. Methods An observational study was conducted on 145 patients who were affected by a (single) ruptured or an unruptured intracranial aneurysm. They were consecutively admitted to 14 Italian hospitals between October 2005 and March 2007. The data collected during the initial hospitalization and three follow-up visits were used to assess the 1-year health costs and the patients' health status after discharge. Two multivariate regression models were used to explain the variability in the acute and post-acute costs. Results The average total cost per patient was €30,813 (evaluation year: 2012). The first model explained the acute costs fairly well and showed that the severity of illness, the admission unit (i.e., intensive care unit vs. another unit of the hospital), and mortality were associated with large, significant (p \ 0.05) coefficients. The second model outperformed the first one in explaining the post-acute costs and showed that health status assessed 30 days after discharge was a significant (p \ 0.05) predictor of costs. Conclusion Policies aimed at containing health costs should focus on interventions that help to reduce disability, which is a key predictor of long-term costs.
The issue of cost is under-investigated for specific forms of cerebrovascular diseases, such as intracranial aneurysms. Intracranial aneurysms are fairly common in the general population: the prevalence estimates indicate that between 0.4 and 6 % of the population will suffer from a cerebral aneurysm in their lifetime [10] . Although most intracranial aneurysms go undetected, acute rupture (resulting in subarachnoid hemorrhage) is associated with 30-67 % mortality and 15-30 % morbidity [11] . To the best of our knowledge, the only recent study to address the issue of cost was published by Dodel and colleagues [12] , who conducted a study on 101 cases of aneurysmal subarachnoid hemorrhage in Germany and showed the significant influence of functional outcome (as measured by the Barthel Index) after 12 months. They focused on 1-year total costs and calculated inpatient care costs using insurance reimbursements and did not control for different therapeutic strategies.
Recent advances in non-invasive imaging techniques have increased the ability of clinicians to diagnose patients with this condition, and the clinical management of aneurysms is currently being debated in the scientific literature. A recent systematic review found no clear consensus on the comparative clinical effectiveness of the two alternate approaches: neurosurgical clipping (hereafter 'clipping') and endovascular coiling (hereafter 'coiling') [13] .
The first objective of the present study was to evaluate the direct health costs associated with 1 year of intracranial aneurysm management for one patient in the Italian National Health System (INHS). Therefore, the study involves several Italian hospitals. Second, the study aimed to assess the extent to which the predictors that are typically used in the literature can explain healthcare costs, but with two additional components: (i) we controlled for the therapeutic approach used, i.e., clipping vs. coiling, and (ii) we separately tested the influence of these predictors on the acute and post-acute costs. In particular, we used two multivariate models: the first model explained the acute and post-acute costs with information gathered at the time of admission (i.e., during the hospitalization period), and the second model explained the post-acute costs with the addition of the clinical outcome assessed 30 days after discharge.
Materials and Methods

Study Design
To measure the direct healthcare costs of intracranial aneurysm management, an observational, prospective, multicenter study was designed. The analysis took the perspective of the NHS. Of the 33 hospitals that were selected according to the criteria described below, 14 voluntarily agreed to participate in the study. We specifically invited hospitals with both neuroradiology and neurosurgery units that performed more than 5 % of the total number of clipping/coiling procedures performed in Italy in 2004. This purposive sampling strategy was intended to control for eventual volume effects in the study design [14] . Hospitals were invited to participate if they made a commitment to provide all data for the entire study period. The neurosurgery and neuroradiology units of the aforementioned 14 hospitals consecutively enrolled patients who had a diagnosis of a (single) ruptured or unruptured intracranial aneurysm that was confirmed after a clinical review and investigations (such as a computerized tomography scan of the brain or a magnetic resonance image). Enrolled patients were treated with either a clipping or a coiling procedure, in accordance with the clinical practice guidelines at each hospital, between October 2005 and March 2007. The enrolled patients had follow-up visits 1, 6, and 12 months after discharge, and information about resource use and health status was gathered during the entire study period, as described in the next section.
Data Collection
The study instruments consisted of four questionnaires (see Appendix 2 in the Electronic Supplementary Material) that were developed and tested with clinicians before they were used in the study. Each questionnaire was used to collect data during the four different phases of the observation period. The first questionnaire-phase one or the acute phase-gathered clinical data (number of bleeding events, the severity of the illness [Hunt & Hess scale, H&H], the aneurysm's location and dimensions, the type of procedure, the admission unit 1 ) and demographic data (gender and age) for each patient. In addition, this questionnaire gathered information about the resources used during hospitalization: length of stay (with a distinction between the intensive care unit [ICU] and other units), diagnostic and laboratory tests, specialist visits, duration of the procedure, number of health professionals in the operating theatre, and time spent by each professional, medical supplies used during the procedure, pharmaceuticals, and rehabilitation therapies. This questionnaire was also used to collect data on the consumption of resources during the first month after discharge as part of the routine practice of all hospitals. The second questionnairephase two-aimed at measuring the patient's health status, in terms of disability as measured with the modified Rankin Scale (mRS), 2 at 1 month after discharge. The third questionnaire-phase three-collected data on the consumption of resources up to the sixth month after discharge: diagnostic and laboratory tests, specialist visits, pharmaceuticals, rehabilitation therapies, re-hospitalization, and consultations with a general practitioner that were related to the aneurysm. Finally, the fourth questionnaire-phase fourgathered data about the consumption of resources during the second half of the follow-up period (i.e., from month 7 to month 12) and the patient's health status 1 year after discharge. All questionnaires were completed by hospital staff members during the patient's hospital stay or during followup visits at the hospital centers. If necessary, the information was collected during phone interviews with the patients or their relatives or caregivers.
Resource Use and Cost Estimation
The consumption of resources was measured using a bottom-up approach (i.e., by reviewing each patient) [15] . The direct healthcare resources consumed by each patient were evaluated in monetary terms using a micro-cost approach. The physical quantities of resources for each patient were analytically recorded, with the exception of pharmaceuticals, whose consumption was estimated on the basis of a random sub-sample of 30 patients [16] , and multiplied by their respective unit costs. Appendix 1 (see the Electronic Supplementary Material) summarizes the cost accounting methods that were adopted to estimate costs for each resource category. The unit costs for instrumental examinations, laboratory tests, primary care visits, and rehabilitation services were based on official reimbursement tariffs. The unit costs for surgical materials were produced by averaging the purchasing costs provided by the accounting departments of the hospitals involved in the study. With regard to the consumption of pharmaceuticals, reference prices from the Italian Drug Agency were used. Finally, overhead costs were estimated using a gross cost method. The aggregated costs (excluding all direct costs) were allocated to each patient according to the appropriate cost drivers (i.e., the number of hospital days and the number of operating room [OR] hours were used to allocate overhead costs and general OR costs, respectively). The overhead costs and the general OR costs were then allocated to single patients according to their length of stay (hospital days) and the duration of their procedure (OR min). The findings are reported in €; the original prices refer to the year 2007 (we adjusted costs to the year 2012 using the consumer price indexes published by the Italian Institute of Statistics-http://www.istat.it-on April 2013.
Data Analysis
All statistical analyses were performed using the software package STATA 11.0 (StataCorp, College Station, TX, USA). Multiple linear regression analyses were performed to identify the predictors of the total treatment costs incurred by the patients during the acute phase (phase one) and the follow-up phases in the observation period. We used two models with different predictors of costs. The first model (model 1) considered all of the patient characteristics and the information available at discharge. As far as the severity of the illness is concerned, our analytical strategy treated the H&H scale as a three-level variable by assigning unruptured cases (H&H = 0) to a reference category, a value of 1 to cases with H&H scores of I and II, and a value of 2 to cases with an H&H score between III and V [12] . The second model (model 2) aimed to assess whether the clinical outcome assessed 1 month after discharge significantly contributed to the post-hospitalization costs; therefore, model 2 also included the mRS score obtained 30 days after the patient's discharge (focusing on survivors). In particular, the clinical outcome was recoded as a dichotomous variable: the patients with no or mild disability (mRS score 0-2) versus the disabled patients (mRS score 3-5) [12] . Mortality was considered among the predictors [17] .
The frequency distribution of the dependent variable was positively skewed, as is usually the case with medical cost data. However, parametric statistical methods are based on the assumption of a Normal distribution of errors. Therefore, we used two different approaches to address this problem in each of the two models and to assess the sensitivity of our results to the estimation method. The first approach used ordinary least squares (OLS) regression to evaluate the influence of each covariate (X i ) on the logarithmically transformed values of our outcome variable (C). This transformation aims to better approximate normality in the distribution of costs. Equation (1) expresses the main features of this approach.
We used the Shapiro-Wilk test to detect significant signs of non-normality in the distribution of the residuals of each model [18] and the variance inflation factor (VIF) to detect problems of multicollinearity [19] . With regard to heteroskedasticity, we performed two tests: the BreuschPagan Lagrange Multiplier test and White's test [20] . In addition, we used three tests to detect group-wise heteroskedasticity: the Levene test and two of its variants proposed by Brown and Forsythe [21] .
We used White-corrected standard errors [22] to cope with the heteroskedasticity detected in our models and compared them with the standard errors obtained with the non-parametric bootstrapping method (validating confidence intervals with 200 iterations) to assess their sensitivity to the nonnormality detected in the models' residuals.
The second approach uses a generalized linear model (GLM), and equation (2) expresses its main features. This model relates the conditional mean (on the raw cost scale) to the covariates through a link function (f) and specifies the relationship between the variance and the mean by selecting a distribution of the linear exponential family. We selected the most appropriate link function and distribution by following the approach suggested by Manning et al. [23, 24] 
This approach has two advantages: (i) it accommodates heteroskedasticity by choosing a distributional family, and (ii) predictions are made on the raw cost scale and can thus easily accommodate heteroskedasticity in more than one regressor. Therefore, we used the selected GLM to obtain the average marginal effects and the direct predictions of the costs. In addition, because the OLS regression on the log-transformed costs consistently estimated parameters, we used its results to assess the robustness of our estimates.
Model 1 considers only the information available for each patient i at the time of discharge. In particular, X i includes the following variables: the patient's age, gender, and severity of illness (H&H); the size of the aneurysm; the location of the aneurysm; mortality at discharge; the type of procedure used (coiling vs. clipping); and the unit of hospitalization (ICU vs. any other unit). Model 2 considers the patients who survived after hospitalization, and X i also includes the mRS score 30 days after the patient's discharge.
Results
Sample Characteristics
A total of 145 patients were enrolled. Tables 1 and 2 show the characteristics of the sample. The majority of the subjects were female, and the average age was approximately 55 years. The clipping approach was used slightly more frequently than the coiling approach, and approximately 26 % of the cases were unruptured aneurysms (H&H = 0). The mortality rate was 16 % (23 cases) during the 1-year observation period; approximately 10 % of the patients were deceased at discharge. Table 2 shows that most of the patients had no or mild disability (mRS = 0-2), including approximately 65 % of patients in phase two and 90 % in phase four.
With regard to costs, the average total cost per patient was €30,813, with high dispersion (SD 30,052) . The last column of Table 3 shows that the majority of costs were incurred during the acute phase. The mean total costs increase along with the H&H and mRS scales, with a few exceptions. The patients who were admitted to ICUs had higher average total costs and a higher proportion of postacute costs than the subjects who were admitted to other units. The same pattern held for patients who underwent the clipping procedure compared with the patients who were treated with the coiling intervention (Table 3) .
Acute Costs Explained with the Information
Available at Discharge (Model 1)
The first model considered all the patients in our sample. The VIF test showed no evidence of multicollinearity (mean VIF = 1.39). However, the Shapiro-Wilk test detected evidence of non-normality in the distribution of the residuals (p \ 0.01). The White test (p = 0.01) and the BreuschPagan test (p \ 0.03) rejected the null hypothesis of constant Table 4 shows the log-OLS regression estimates using White-corrected standard errors. These errors are very similar to the results produced by the bootstrapping method, thus confirming that the model has negligible sensitivity to the non-normality detected in the residuals. Severity of illness, mortality at discharge, and admission to the ICU have significant coefficients and a large impact on acute costs. Compared with patients with unruptured aneurysms, the patients with H&H scores I or II and the patients with H&H scores III-V incurred on average approximately 33 and 75 % higher costs, respectively, with other conditions being equal. Mortality at discharge was associated with approximately 37 % lower expected costs, and patients who were admitted to ICUs tended to have approximately 34 % higher costs than the patients who were hospitalized in other units, other things being equal. The model explains approximately 38 % of the observed variability. The last column of Table 4 shows the results of a GLM estimation based on a Gamma distribution and a log link function. It provides estimates that are similar to the results of the log-OLS regression, thus confirming that these estimates are robust.
The estimated average acute costs totaled €26,220, and the last column of Table 4 shows how the costs vary across predictors in terms of average marginal effects.
Post-acute Costs Explained by Model 1 and Model 2
We first analyzed the post-acute costs with Model 1. After the logarithmic transformation of the dependent variable, we found no evidence of multicollinearity (mean VIF = 1.38). The Shapiro-Wilk test detected evidence of a non-Normal distribution of the residuals. The Levene test and its variants did not allow us to reject the presence of a correlation between the variance of the error term and the covariates of admission unit and severity of illness (p \ 0.05). Therefore, we replicated the approach that we used for the acute costs. The first column of Table 5a shows the log-OLS estimates using White-corrected standard errors. None of the variables had significant coefficients, and the model explained approximately 15 % of the observed variability in the post-acute costs. The last column of Table 5a shows the results of a GLM estimation based on a Gamma distribution and a log link function. The results of the two estimation approaches are different, thus raising concerns about consistency. Model 2 also included health status as assessed 30 days after discharge and focused on survivors in the second phase of the study. The analytical strategy included the same steps described for the previous model. The tests we performed did not reveal multicollinearity (mean VIF = 1.34); however, evidence of a non-Normal distribution and signs of heteroskedasticity was detected in the log-scale residuals. Therefore, we replicated the approach that we used for the previous model.
The first column of Table 5b shows the log-OLS estimates using White-corrected standard errors. These errors were very similar to the results produced by the bootstrapping method, thus confirming that the model has negligible sensitivity to the non-normality detected in the residuals. Health status 1 month after discharge had a significant influence on post-acute costs. In particular, if other conditions were equal, the patients with scores between 3 and 5 on the mRS scale were likely to incur costs as much as 89 % higher than the subjects who were asymptomatic or who experienced mild disability. The model explained almost 20 % of the variability observed in the post-acute costs, 3 and the results were consistent across the two estimation approaches, with the exception of the admission unit covariate, which was significant only with the GLM approach. Therefore, including information about health status 30 days after discharge produces reliable results.
The estimated average post-acute costs totaled €5,270, and the last column of Table 5b shows the variation in costs across the predictors in terms of marginal average effects.
Discussion
Technology in healthcare is developing at a faster rate than the available resources. Economic evaluations of different treatment strategies and health technology assessments (HTA) are important for supporting decision-making processes concerning the allocation of scarce resources [25] [26] [27] [28] , especially in an era of major concerns about increasing non-communicable diseases in all countries [29] .
In this respect, to the best of our knowledge, this is the first empirical study that has investigated the costs of treating aneurysms in Italy and shown that it is a costly disease. Our results show that the severity of illness at admission, admission to the ICU, and mortality at discharge play a significant role in explaining the acute costs per patient. These three covariates positively impact acute costs by double-digit percentages. These results confirm the findings reported in current studies [3] [4] [5] [6] [7] [8] [9] 12] , which typically include acute costs or total costs (i.e., acute and post-acute costs). Interestingly, our study shows that health status (in terms of disability) 30 days after discharge is a reliable and important predictor of the post-acute costs incurred by the patients.
When considering post-acute health costs separately, the typical predictors based on information available at discharge do not consistently explain the observed variability. In fact, our results are not consistent across the different estimation approaches. However, with the inclusion of health status 30 days after discharge, our results are rather stable and confirm that disability after discharge has a significant and substantial effect on post-acute costs.
The present study can help to inform policy makers' decisions about new therapeutic strategies. New interventions are entering the healthcare market at an increasingly rapid pace, but due to budget constraints and heavy cost containment measures, the costs of new therapies must be assessed against their incremental effectiveness before introducing them into a publicly financed system. As far as the INHS is concerned, policy makers seem reluctant to use economic evidence to make decisions about the introduction of new procedures, even though recent evidence suggests an increasing interest in HTA and economic evaluations [30] . Our results highlight the fact that any intervention/procedure aimed at decreasing patients' disability is likely to have a major impact on post-acute costs. This result suggests that the incremental costs associated with a new intervention could be assessed against the potential savings that the INHS could collect from the reduction in disability. However, assessments of innovative technologies for treating aneurysm should be made in the wider context of priority setting in healthcare, because decision-making is an intrinsically complex endeavor that uses different and often contrasting criteria, ranging from clinical effectiveness and economics to equity and social impact.
Despite the technical efforts we made to increase the robustness of our results, they should be interpreted with caution. First, given the exploratory nature of the study and the limited resources available, conducting an investigation in a fully representative sample of hospitals across the country was not feasible. Thus, the limited sample size and voluntary nature of participation for the hospitals (which may have introduced self-selection bias) prevent us from generalizing the results to the INHS. However, a limited number of socio-demographic characteristics (age and gender) show that our sample was fairly representative of the patients with intracranial aneurysms who were treated in Italy in 2004. 4 In addition, despite the aforementioned limitations and the specific social, economic, and cultural characteristics of the INHS, our results confirm the other findings in the international literature concerning the acute costs of intracranial aneurysm management.
Conclusions
The average total cost of managing an intracranial aneurysm is €30,813 per patient. Disability status 30 days after discharge is a key factor in explaining direct health costs. Therefore, any intervention that can help reduce disability after discharge is likely to significantly decrease future health costs.
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